Other than cramer running off and not doing his home work with his puppet...You find me one thing backed up with credible documentation and post it here..
Sentiment: Strong Buy
ovio Pharmaceuticals Inc (INO) on May 16, 2016 announced that testing of its synthetic vaccine for the Zika virus induced robust antibody and T cell responses in non-human primates (monkeys), demonstrating the product’s potential to prevent infection from this harmful pathogen.
Inovio synthetically generated DNA vaccine constructs targeting multiple Zika virus antigens using its SynCon vaccine technology. These SynCon constructs were administered using Inovio’s CELLECTRA® electroporation delivery technology. Two doses of the Zika DNA vaccine delivered either intramuscularly or intradermally resulted in seroconversion, or the development of detectable specific antibodies in the blood, in all vaccinated non-human primates. Researchers also observed that vaccination generated robust and broad T cell responses as analyzed by the standardized T cell ELISPOT assay. These findings are vital given the potential importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.
Sentiment: Strong Buy
in the stock by 2.25% over the past 6 months. Insiders now own 4.00% of total outstanding shares.
There are both legal and illegal types of insider trading. Illegal insider trading is the buying or selling of a stock by insiders who are in possession of knowledge that has yet to be made public. Anybody who has this information can be convicted of insider trading, including brokers, family, friends and employees, not just upper management. The Securities and Exchange Commission (SEC) is very strict with those who trade illegally because the practice undermines investor confidence and the integrity of the market. “Tipsters”, people who give insider information to outsiders, can also be found liable.
Insider trading isn’t always illegal, however. Insiders buy and sell their own company’s stock all the time, though their trading is restricted. The SEC considers an “insider” to be any individual who possesses at least a 10% stake in the company. These insiders are required to report their transactions within two business days of the transaction date.
This information is valuable to individual investors. If insiders are buying stock in their own companies, they might know something that a normal investor does not. Insiders are prevented from trading their company stock within a six-month period, therefore it can be assumed that insiders buy their own stocks because they feel that their company will perform well over a long period of time. Peter Lynch, regarded as one of the greatest investors of all time, notes “insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.”
Sentiment: Strong Buy
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments. The study will enroll patients who are in the early stages of chronic HCV infection to determine the therapy’s ability to decrease and potentially eliminate HCV viral load, measure HCV specific immune responses and durability of these immune responses, and evaluate safety and tolerability. In this dose-escalation study INO-8000 will be combined with increasing doses of DNA-based IL-12 (INO-9012), an immune activator, which in previous studies has been shown to increase the therapeutic immune response to DNA immunotherapies.
The study is funded by the National Cancer Institute’s Division of Cancer Prevention and will be conducted at the Mayo Clinic and other U.S. sites.
Among those initially infected with HCV, 75 to 85 percent will go on to develop chronic illness. More than 170 million people around the world are chronically infected with HCV. According to the U.S. Centers for Disease Control (CDC) an estimated 3.5 million people in the US are chronically infected with HCV, with about 20,000 new cases of chronic HCV reported in the US in the last year. About 15,000 people in the US die each year of HCV-related causes.
Inovio's SynCon® DNA immunotherapy, INO-8000, is encoded for the antigens NS3/4A, NS4B, and NS5A of HCV genotypes 1a and 1b, the most difficult-to-treat genotypes. The product is designed to induce robust T cells to eliminate cells displaying these antigens and has been shown in published preclinical studies to generate powerful HCV-specific T cell responses throughout the body and in the liver.
Dr. Jeffrey Jacobson, the study’s Principal Investigator, said “Development of a vaccine therapy against hepatitis C would be important as a less expensive, simpler treatment alternative to several months of medication that should encourage better patient compliance, particularly in difficult-to-treat patient populations. It also holds the promise of inducing immunity protective against re-infection in patients who continue to be exposed, a not uncommon problem.” Dr. Jacobson is Professor of Medicine, Neuroscience and Neurovirology at the Lewis Katz School of Medicine, Temple University.
Dr. J. Joseph Kim, President and CEO, said, “Despite recent treatment advances, HCV infection remains a burden on our healthcare and payor system and continues to spread. Today’s expensive drugs are highly effective in treating HCV but are not available to the majority of infected individuals. We are pleased to join the NCI and Mayo Clinic in this quest to develop an alternative medical solution to fight this disease, which remains one of the fastest-developing markets in healthcare."
Inovio previously announced that it signed a collaborative agreement with GeneOne Life Sciences to develop INO-8000, along with a DNA IL-28 immune activator, in drug-resistant HCV patients in a phase I study in Korea. That study is on-going.
, tolerable, and generated strong T cell and antibody responses in its fully enrolled phase I study of 75 healthy subjects. Detailed immunogenicity and safety data is being prepared for peer-reviewed publication. In previously reported preclinical testing in mice and non-human primates, the Ebola vaccine protected 100% of immunized animals from sickness and death following exposure to a lethal dose of Ebola virus.
This human study (CT.gov: NCT02464670) was conducted by an Inovio-led consortium, which was selected and awarded $45 million by the U.S. Defense Advanced Research Projects Agency (DARPA) in 2015 to take a multi-faceted approach to prevent and treat Ebola infection.
This initial trial evaluated INO-4212 in five groups of healthy subjects. INO-4212 consists of two optimized SynCon® DNA plasmids coding for the Ebola glycoprotein antigen from circulating Ebola strains from 1975 - 2014. These plasmids were tested separately and together in muscle and skin in five study arms, one including Inovio’s DNA-based IL-12 immune activator. Of 69 evaluated subjects, 64 (92.7%) seroconverted and mounted a strong antibody response to the Ebola glycoprotein antigen following the three dose immunization regimen; 48 subjects (69.6%) seroconverted after only two doses.
Significantly, in the study arm using intradermal (skin) administration, 13 of 13 evaluable subjects (100%) generated antigen-specific antibody responses after only two doses and all remained seropositive after three immunizations. Similarly, in the study arm receiving the vaccine with intramuscular administration in combination with plasmid IL-12, 12 of 13 evaluable subjects (92.3%) demonstrated strong antibody responses after only two immunizations and 13 of 13 (100%) produced strong antibody responses after three immunizations.
The Ebola glycoprotein specific geometric mean antibody titers measured in the five cohorts ranged from over 2,000 to greater than 46,000. Significantly, a majority of vaccinated subjects in each of the five cohorts produced strong Ebola antigen specific T-cell responses as measured by interferon gamma ELISpot analysis.
To date INO-4212 has been well tolerated and has not demonstrated systemic serious adverse effects, such as fever, joint pain, and low white blood cell counts, reported in association with some viral vector based Ebola vaccines currently in development. Moreover, unlike the viral vectored vaccines which must be kept frozen, INO-4212 was formulated in a solution which was kept refrigerated (2-8 C).
The data was presented today by Dr. Niranjan Y. Sardesai, Inovio’s Chief Operating Officer and Principal Investigator on the DARPA Ebola program, at The World Vaccine Congress in Washington, DC. Dr. Sardesai said, “The induction of strong Ebola specific antibody and T cell responses has been difficult to achieve in previous human studies. We are pleased by the immune responses achieved using two and three vaccination regimens in humans with our optimized DNA vaccines delivered using electroporation, adding to the successful animal immune response and challenge studies using our approach. We are particularly excited about the positive immunology data using intradermal immunization as this delivery would facilitate even greater clinical and commercial potential for DNA vaccination.”
“These initial data from our Ebola DNA vaccine represent just a first step in this DARPA-funded program. We look forward to rapidly moving this DNA vaccine into larger human studies on the path to product licensure. We are also advancing our Ebola dMAb™ product and expect to clinically test that independently of the DNA vaccine approach,” said Dr. J. Joseph Kim, President and CEO.
Inovio Pharmaceuticals logoInovio Pharmaceuticals Inc (NASDAQ:INO) Director Morton Collins acquired 10,000 shares of Inovio Pharmaceuticals stock in a transaction on Tuesday, June 28th. The stock was purchased at an average cost of $9.13 per share, for a total transaction of $91,300.00. Following the purchase, the director now owns 142,291 shares in the company, valued at $1,299,116.83. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) traded up 2.39% during trading on Wednesday, hitting $9.43. The stock had a trading volume of 2,246,089 shares. The firm’s 50-day moving average is $10.42 and its 200 day moving average is $8.16. Inovio Pharmaceuticals Inc has a 52-week low of $4.50 and a 52-week high of $11.69. The firm’s market cap is $689.30 million.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.03. The business had revenue of $8.10 million for the quarter, compared to the consensus estimate of $4.75 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. On average, analysts expect that Inovio Pharmaceuticals Inc will post ($0.75) EPS for the current year.
Oh, and all the profit we've made so far...it's a trick.Stay short,I'll tell you when to cover..Gary loves you..
Sentiment: Strong Buy
Seems we are rite on track.As per INOVIO, The Head and Neck program is progressing nicely. NOTHING has changed..When was the last time you read bad published news outside the posts of some of the morons on this board..
I post facts....not dribble..
“insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.”
Sentiment: Strong Buy
Dr. Kim will discuss Inovio’s Zika vaccine preclinical developments on June 16, 2016 at an international forum hosted and organized by the Foundation for Vaccine Research and The National Academy of Medicine called “Ebola, SARS, MERS, Nipah, Zika Virus and Beyond: Challenges and Opportunities for Vaccine Development” in Washington DC. This high-level international forum is an invitation-only 1½ day event for decision-makers from the public and private sectors.
Human trials for Zika Virus ..40 healthy subjects...it now starts for us and ehds for the shorts..As Trump would say "by by "..Or buy buy..
Sentiment: Strong Buy
So...eat your heart out..................shorts..
Sentiment: Strong Buy
Inovio Pharmaceuticals Inc (INO) on May 04, 2016 announced it will exhibit the breadth and promise of its cancer and infectious disease immunotherapy, vaccine and DNA-based monoclonal antibody (dMAb) pipeline in 10 presentations at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held in Washington, DC from May 4-7.
The ASGCT abstract review committee selected Inovio’s presentation of its successful preclinical Ebola vaccine development for one of only three presentations to be given at its prestigious Presidential Symposium. In the selected abstract, out of 768 submitted and accepted, the presented preclinical testing in mice and non-human primates showed Inovio’s Ebola vaccine protected 100% of immunized animals from sickness and death following exposure to a lethal dose of Ebola virus. Those results led to a study of 75 healthy subjects which showed the vaccine was safe, tolerable, and generated strong T cell and antibody responses in human as well.
Inovio’s Ebola results will be offered on Friday, May 6, at 2:50 p.m. in a presentation entitled: “479 – An Optimized DNA Vaccine Formulation Protects Against Lethal Ebola Makona Virus Challenge in Non-Human Primates and Elicits Robust Immune Responses.”
Dr. J. Joseph Kim, President and CEO, said, “The results we will present at the ASGCT global scientific forum demonstrate the potential and breadth of the three pillars of Inovio’s broad pipeline: Immunotherapies and vaccines against cancers and challenging infectious diseases and our DNA-encoded monoclonal antibodies (dMAbs), which we believe will offer clear advantages over conventional monoclonal antibody technologies including faster development, easier product manufacturing, and more favorable pharmacokinetics.”
will takeoff tomorrow..
Sentiment: Strong Buy
NASDAQ:INO) has received the green light to proceed with the initial Phase 1 study of its Zika vaccine drug candidate GLS-5700 in humans. With the latest development, Inovio has effectively jumped ahead of Sanofi SA (NYSE:SNY), which is also working on a potential Zika vaccine. Several other drug companies including Pfizer, Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) are also said to be weighing their options regarding entering the Zika vaccine research ring.
Inovio Pharmaceuticals’ candidate GLS-5700 is a product of collaboration with South Korea’s GeneOne and academic researchers in the U.S. and Canada. The approval for human trial of GLS-5700 now increases pressure on Inovio’s rivals who are also working on Zika virus medicines.
A global health concern
Zika virus outbreak is said to have spread to about 58 countries and territories. Given the threat of the virus and how rapidly it is spreading, the World Health Organization (WHO) has declared it a global public health emergency. Zika virus has been linked to severe birth defects where babies are born with abnormally smaller head, a condition that is medically known as microcephaly. The condition arises when a pregnant woman is infected by the virus. In other people, Zika infection causes fever, joint pain, conjunctivitis and rash.
The rapid spread of Zika infection and the birth defects it causes has increased the urgency in developing a treatment for the virus to keep global populations healthy. Among pharmaceutical companies that have thrown their hat in the Zika ring, Inovio Pharmaceuticals appears to be taking the lead with human trial of its compound GLS-5700
The most recent analyst ratings issued by brokerages:
06/21/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 17 price target on the stock.
06/21/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Rodman & Renshaw. They now have a USD 17 price target on the stock.
06/20/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 14 price target on the stock.
05/09/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 13 price target on the stock.
03/15/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 18 price target on the stock.
02/19/2016 – Inovio Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 31 price target on the stock.
05/18/2015 – Inovio Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 9 price target on the stock.
Time is on Inovios' side..Wister for manufacturing, and the recent stock purchase by insider and not to forget the purchase of needle-free injection technology.Support of the goal of non-invasive administration, the U.S. Army Small Business Innovation Research program recently granted Inovio $500,000 to support the development of a needle-free, non-invasive skin-surface electroporation device for DNA vaccine delivery.